Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis.

Mazze R, Strock E, Morgan B, Wesley D, Bergenstal R, Cuddihy R

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 May 2009Cited by 20 (Europe PMC)

PMID19454385DOI10.4158/ep09046.orrPepBankPUB-19454385

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In the diabetes subgroup, once-weekly exenatide reduced HbA1c from baseline at 30 weeks.
In plain wordsIn the diabetes subgroup, weekly exenatide reduced HbA1c compared with baseline at 30 weeks.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c at 30 weeks
Study
n = 7
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
once weekly · 30 weeksAs given in this study (human).
Measurements
HbA1c reduction
1.3%
30 weeks
Source sentences
Summary
At 30 weeks and 52 weeks, participants treated with exenatide once weekly had a mean reduction in hemoglobin A1c level of 1.3 +/- 0.3% and 1.0 +/- 0.3%, respectively (P<.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Seven of the 303 patients in the larger study population were included in the subgroup analysis.
Summary · context
We performed a subgroup analysis of patients with type 2 diabetes who participated in a multicenter trial (DURATION-1: Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus) comparing once-weekly with twice-daily formulations of exenatide.
Summary · context
We are the only center to use CGM with ambulatory glucose profile (AGP) analysis to characterize glucose exposure, variability, and stability in participants assigned to exenatide once weekly.
Report a problemFND-1945438501
02HumanNon-randomized trialEfficacy outcome
In the diabetes subgroup, once-weekly exenatide reduced HbA1c from baseline at 52 weeks.
In plain wordsIn the diabetes subgroup, weekly exenatide reduced HbA1c compared with baseline at 52 weeks.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c at 52 weeks
Study
n = 7
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
once weekly · 52 weeksAs given in this study (human).
Measurements
HbA1c reduction
1%
52 weeks
Source sentences
Summary
At 30 weeks and 52 weeks, participants treated with exenatide once weekly had a mean reduction in hemoglobin A1c level of 1.3 +/- 0.3% and 1.0 +/- 0.3%, respectively (P<.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Seven of the 303 patients in the larger study population were included in the subgroup analysis.
Summary · context
We performed a subgroup analysis of patients with type 2 diabetes who participated in a multicenter trial (DURATION-1: Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus) comparing once-weekly with twice-daily formulations of exenatide.
Summary · context
We are the only center to use CGM with ambulatory glucose profile (AGP) analysis to characterize glucose exposure, variability, and stability in participants assigned to exenatide once weekly.
Report a problemFND-1945438502
03HumanNon-randomized trialEfficacy outcome
In the diabetes subgroup, once-weekly exenatide reduced nocturnal and daytime glucose exposure in four participants.
In plain wordsIn the diabetes subgroup, weekly exenatide reduced day and night glucose exposure compared with baseline in four participants.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseDiurnal glucose exposure
Study
n = 7
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
once weeklyAs given in this study (human).
Measurements
Participants with decreased exposure
4 participants
nocturnal and daytime
Source sentences
Summary
CGM analysis revealed a significant (P<.01) decrease in diurnal glucose exposure for 4 participants during nocturnal and daytime periods.
3 context sentences(design, population, supporting numbers)
Summary · context
Seven of the 303 patients in the larger study population were included in the subgroup analysis.
Summary · context
We performed a subgroup analysis of patients with type 2 diabetes who participated in a multicenter trial (DURATION-1: Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus) comparing once-weekly with twice-daily formulations of exenatide.
Summary · context
We are the only center to use CGM with ambulatory glucose profile (AGP) analysis to characterize glucose exposure, variability, and stability in participants assigned to exenatide once weekly.
Report a problemFND-1945438503
04HumanNon-randomized trialEfficacy outcome
In the diabetes subgroup, excess glucose exposure decreased in six of seven participants receiving once-weekly exenatide.
In plain wordsIn the diabetes subgroup, excess glucose exposure decreased from baseline in six of seven weekly exenatide recipients.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseExcess glucose exposure
Study
n = 7
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
once weeklyAs given in this study (human).
Measurements
Participants with decreased excess exposure
6 participants
exenatide once weekly
Source sentences
Summary
Excess glucose exposure (compared with reference values) decreased in 6 of 7 participants, as did glucose variability.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a subgroup analysis of patients with type 2 diabetes who participated in a multicenter trial (DURATION-1: Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus) comparing once-weekly with twice-daily formulations of exenatide.
Summary · context
We are the only center to use CGM with ambulatory glucose profile (AGP) analysis to characterize glucose exposure, variability, and stability in participants assigned to exenatide once weekly.
Report a problemFND-1945438504
05HumanNon-randomized trialEfficacy outcome
In the diabetes subgroup, glucose variability decreased in six of seven participants receiving once-weekly exenatide.
In plain wordsIn the diabetes subgroup, glucose variability decreased from baseline in six of seven weekly exenatide recipients.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose variability
Study
n = 7
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
once weeklyAs given in this study (human).
Measurements
Participants with decreased glucose variability
6 participants
exenatide once weekly
Source sentences
Summary
Excess glucose exposure (compared with reference values) decreased in 6 of 7 participants, as did glucose variability.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a subgroup analysis of patients with type 2 diabetes who participated in a multicenter trial (DURATION-1: Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus) comparing once-weekly with twice-daily formulations of exenatide.
Summary · context
We are the only center to use CGM with ambulatory glucose profile (AGP) analysis to characterize glucose exposure, variability, and stability in participants assigned to exenatide once weekly.
Report a problemFND-1945438505
06HumanNon-randomized trialEfficacy outcome
In the diabetes subgroup, glucose stability improved in five participants receiving once-weekly exenatide.
In plain wordsIn the diabetes subgroup, glucose stability improved from baseline in five weekly exenatide recipients.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGlucose stability
Study
n = 7
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
once weeklyAs given in this study (human).
Measurements
Participants with improved glucose stability
5 participants
exenatide once weekly
Source sentences
Summary
Glucose stability improved in 5 participants.
3 context sentences(design, population, supporting numbers)
Summary · context
Seven of the 303 patients in the larger study population were included in the subgroup analysis.
Summary · context
We performed a subgroup analysis of patients with type 2 diabetes who participated in a multicenter trial (DURATION-1: Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus) comparing once-weekly with twice-daily formulations of exenatide.
Summary · context
We are the only center to use CGM with ambulatory glucose profile (AGP) analysis to characterize glucose exposure, variability, and stability in participants assigned to exenatide once weekly.
Report a problemFND-1945438506
07HumanNon-randomized trialSafety outcome
In the diabetes subgroup, low glucose readings initially increased with once-weekly exenatide, then returned to baseline by study end.
In plain wordsIn the diabetes subgroup, low glucose readings initially increased during weekly exenatide treatment, then returned to baseline.
Peptide
Exenatide (exendin-4)
Outcome
MixedGlucose values below 70 mg/dL
Study
n = 7
Comparator
Baseline
Outcome group
Adverse events · Metabolic and weight
Studied dose
once weeklyAs given in this study (human).
Source sentences
Summary
The percentage of glucose values less than 70 mg/dL initially increased during the first half of the study then decreased to baseline levels by study end.
3 context sentences(design, population, supporting numbers)
Summary · context
Seven of the 303 patients in the larger study population were included in the subgroup analysis.
Summary · context
We performed a subgroup analysis of patients with type 2 diabetes who participated in a multicenter trial (DURATION-1: Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus) comparing once-weekly with twice-daily formulations of exenatide.
Summary · context
We are the only center to use CGM with ambulatory glucose profile (AGP) analysis to characterize glucose exposure, variability, and stability in participants assigned to exenatide once weekly.
Report a problemFND-1945438507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT01089569

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

HealthPartners Instituten = 60Apr 2010 to May 2013

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 23 May 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.